Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19) (DECOR-19)

July 25, 2020 updated by: Treviso Regional Hospital

DElayed COloRectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)

To understand and analyse the global impact of COVID-19 on outpatient services, inpatient care, elective surgery, and perioperative colorectal cancer care, a DElayed COloRectal cancer surgery (DECOR-19) survey was conducted in collaboration with numerous international colorectal societies with the objective of obtaining several learning points from the impact of the COVID-19 outbreak on our colorectal cancer patients which will assist us in the ongoing management of our colorectal cancer patients and to provide us safe oncological pathways for future outbreaks.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1051

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Treviso, Italy
        • Treviso Regional Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The survey link was sent to scientific societies of interest to coloproctologists and disseminated to their members. Participation was entirely voluntary with no compensation offered. Informed consent was obtained from all those agreeing to complete a survey. This study was exempt from review board approval at authors' institutions.

Description

Inclusion Criteria:

  • Members of renowned scientific societies with an interest in coloproctology

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions
Time Frame: 20 days
Respondents' and hospitals' demographics include: gender, country of origin, type of hospital (i.e. academic or not), type of unit (general surgery vs. colorectal), no. hospital beds, no. yearly surgeries for colon and rectal cancer, hospital preparedness to the emergency (i.e. fully or partially dedicated or not involved in COVID-19 care), readily availability of external facilities for colorectal cancer surgery, cancer care coordinator, personal protective equipment, status of elective surgery, no. elective colorectal cancer patients needing urgent surgery, any change in the original management plan, no. colorectal cancer patients refusing surgery or being COVID-19 + on surgery or becoming COVID-19 + post-operatively, no. staff members quarantined or relocated in COVID-19 units, MDT meeting suspension, any delay in endoscopy, radiology, oncology, surgery, histopathology.
20 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Treviso Regional Hospital

Collaborators

Gaetano Gallo
Gian Luca Di Tanna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2020

Primary Completion (Actual)

June 10, 2020

Study Completion (Actual)

June 10, 2020

Study Registration Dates

First Submitted

July 23, 2020

First Submitted That Met QC Criteria

July 25, 2020

First Posted (Actual)

July 28, 2020

Study Record Updates

Last Update Posted (Actual)

July 28, 2020

Last Update Submitted That Met QC Criteria

July 25, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Treviso

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rectal Cancer

Clinical Trials on Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe